Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
Oh, those weekends, don’t you just love them? They provide us with an opportunity to spend time with our families, drive to the country house or go to the theater. Now, we know they also provide us with an increased opportunity to die in a hospital. Research shows that men with metastatic prostate cancer who [...]
I attend the American Society of Clinical Oncology (ASCO) meeting in Chicago in May. As usual, it was exciting and it provides me with a fantastic opportunity to catch up with the current research in advanced prostate cancer. It also gives me an opportunity to meet with and have private conversations with some of the [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]
Click Here to Take the Prostate Cancer Experience The Prostate Cancer Experience study at will help us understand the truth of how prostate cancer treatment affects day to day living. There are many different kinds of treatments, different stages of disease and different sequences of treatment choice making. The Prostate Cancer Experience encompasses all of [...]
The line item for FY 2016 CDC prostate cancer funding of $13,205,000 is restored in both the House and Senate appropriations bills, as authored by their committees. Thanks to the several thousand of you who responded to Malecare's call to action and wrote emails and letters to the Congressional House and Senate Budget Committee. Since both [...]
In the treatment of prostate cancer the first very expensive drug we had that was FDA approved was Provenge, with an initial cost of $93,000 for a one-month’s treatment protocol. Today, the cost is in excess of $106,000. According to the phase III clinical trial result Provenge extends life by a median of 4.1 months, [...]
Yesterday, the United States Senate debated the Defense Spending Bill. As expected Senator McCain’s amendment came up for debate. I have attached a link to the Congressional Record, which includes both Senator McCain’s remarks against continuing support for the Congressionally Directed Medical Research Programs as well as Senator Durbin’s response. If you are interested in [...]
The problems created by Senator McCain continue to be ever present. Our friend, Senator Durbin has asked that we provide his office with additional background about the military nature of the research performed by the Congressionally Directed Medical Research Programs (CDMRP), including the Prostate Cancer Research Program (PCRP). In addition there is a very misguided [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]
